BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16780731)

  • 1. [Research on demethylation therapy for hematology malignancy].
    Shen JZ; Zhou HR
    Zhonghua Nei Ke Za Zhi; 2006 May; 45(5):355-6. PubMed ID: 16780731
    [No Abstract]   [Full Text] [Related]  

  • 2. Epigenetic treatment of hematopoietic malignancies: in vivo targets of demethylating agents.
    Claus R; Almstedt M; Lübbert M
    Semin Oncol; 2005 Oct; 32(5):511-20. PubMed ID: 16210092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hematologic malignancies /pediatric malignancies-current status of molecular target therapy for hematologic cancer].
    Usui N
    Gan To Kagaku Ryoho; 2010 May; 37(5):805. PubMed ID: 20524247
    [No Abstract]   [Full Text] [Related]  

  • 4. Role of epigenetic changes in hematological malignancies.
    Lehmann U; Brakensiek K; Kreipe H
    Ann Hematol; 2004 Mar; 83(3):137-52. PubMed ID: 15064862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Epigenetics in hematological disorders].
    Furukawa Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1472-82. PubMed ID: 18833931
    [No Abstract]   [Full Text] [Related]  

  • 6. [Analysis for hematopoietic disorder using DNA methylation as a molecular marker].
    Uchida T; Fukuda T
    Rinsho Ketsueki; 2000 May; 41(5):380-5. PubMed ID: 10879095
    [No Abstract]   [Full Text] [Related]  

  • 7. Demethylation of DNA by decitabine in cancer chemotherapy.
    Brown R; Plumb JA
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):501-10. PubMed ID: 15270655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ambulatory chemotherapy in hematology. A challenge ...].
    Montagne C; Duran B
    Soins; 1996 Sep; (608):62-8. PubMed ID: 8954491
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug resistance in hematologic malignancies: induction mechanisms, genetics, and therapeutics.
    Zhan F; Zangari M; Qiu L
    Biomed Res Int; 2015; 2015():384575. PubMed ID: 26000289
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanisms of drug resistance in hematologic malignancies.
    Dalton WS
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):3-8. PubMed ID: 9408955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Hematology: experiences with common national reports on new anti-cancer drugs].
    Kristensen JS; Bukh A
    Ugeskr Laeger; 2009 Mar; 171(13):1089. PubMed ID: 19321084
    [No Abstract]   [Full Text] [Related]  

  • 12. [Antineoplastic agents and biologic response modifiers in oncologic hematology].
    Cabrera Marín JR; Briz del Blanco M
    Rev Clin Esp; 1999 Apr; 199 Suppl 1():3-13. PubMed ID: 10422445
    [No Abstract]   [Full Text] [Related]  

  • 13. Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies.
    Wang LQ; Liang R; Chim CS
    Expert Rev Mol Diagn; 2012 Sep; 12(7):755-65. PubMed ID: 23153241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Bishton M; Kenealy M; Johnstone R; Rasheed W; Prince HM
    Expert Rev Anticancer Ther; 2007 Oct; 7(10):1439-49. PubMed ID: 17944568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epigenome in hematopoietic malignancies].
    Iwama A
    Rinsho Ketsueki; 2011 Oct; 52(10):1687-95. PubMed ID: 21971247
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hematologic malignancies/pediatric malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2012 May; 39(5):731. PubMed ID: 22701898
    [No Abstract]   [Full Text] [Related]  

  • 17. [Study on DNA methylation status of WT1 gene in its promoter region in hematologic malignancy cell lines].
    Zhao Y; Chen ZX; Hu SY; Cen JN; Gu WY
    Zhonghua Xue Ye Xue Za Zhi; 2005 Sep; 26(9):517-20. PubMed ID: 16468326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene silencing by DNA methylation in haematological malignancies.
    Boultwood J; Wainscoat JS
    Br J Haematol; 2007 Jul; 138(1):3-11. PubMed ID: 17489980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. To cap or not to cap: chemotherapy dosing in obese adult hematology patients.
    Sandhu G; Mapp S; Carrington C; Hennig S
    Clin Pharmacol Ther; 2014 Apr; 95(4):356-8. PubMed ID: 24646484
    [No Abstract]   [Full Text] [Related]  

  • 20. Signal transduction therapy in haematological malignancies: identification and targeting of tyrosine kinases.
    Chase A; Cross NC
    Clin Sci (Lond); 2006 Oct; 111(4):233-49. PubMed ID: 16961463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.